Prediction of mental illness in heart disease patients: association of comorbidities, dietary supplements, and antibiotics as risk factors by Sivakumar, Jayanth et al.
Binghamton University 
The Open Repository @ Binghamton (The ORB) 
Health & Wellness Studies Faculty Scholarship Decker School of Nursing 
11-9-2020 
Prediction of mental illness in heart disease patients: association 







Follow this and additional works at: https://orb.binghamton.edu/hws_fac 





Prediction of Mental Illness in Heart Disease Patients:
Association of Comorbidities, Dietary Supplements,
and Antibiotics as Risk Factors
Jayanth Sivakumar 1 , Saba Ahmed 2, Lina Begdache 3 , Swati Jain 4 and Daehan Won 1,*
1 Department of Systems Science and Industrial Engineering, The State University of New York at
Binghamton, Binghamton, NY 13902, USA; jsivaku1@binghamton.edu
2 Department of Biological Sciences, The State University of New York at Binghamton,
Binghamton, NY 13902, USA; sahmed55@binghamton.edu
3 Health and Wellness Studies Department, The State University of New York at Binghamton,
Binghamton, NY 13902, USA; lbegdac1@binghamton.edu
4 Department of Computer Science and Engineering, Institute of Technology, Nirma University,
Ahmedabad, Gujarat 382470, India; swati.jain@nirmauni.ac.in
* Correspondence: dhwon@binghamton.edu; Tel.: +1-607-777-5024
Received: 11 September 2020; Accepted: 5 November 2020; Published: 9 November 2020 
Abstract: Comorbidities, dietary supplement use, and prescription drug use may negatively
(or positively) affect mental health in cardiovascular patients. Although the significance of mental
illnesses, such as depression, anxiety, and schizophrenia, on cardiovascular disease is well documented,
mental illnesses resulting from heart disease are not well studied. In this paper, we introduce the
risk factors of mental illnesses as an exploratory study and develop a prediction framework for
mental illness that uses comorbidities, dietary supplements, and drug usage in heart disease patients.
Particularly, the data used in this study consist of the records of 68,647 patients with heart disease,
including the patient’s mental illness information and the patient’s intake of dietary supplements,
antibiotics, and comorbidities. Patients in age groups < 61, gender differences, and drug intakes,
such as Azithromycin, Clarithromycin, Vitamin B6, and Coenzyme Q10, were associated with mental
illness. For predictive modeling, we consider applying various state-of-the-art machine learning
techniques with tuned parameters and finally obtain the following: Depression: 78.01% accuracy,
79.13% sensitivity, 72.65% specificity, and 86.26% Area Under the Curve (AUC). Anxiety: 82.93%
accuracy, 82.86% sensitivity, 83.35% specificity, and 88.45% AUC. Schizophrenia: 87.59% accuracy,
87.70% sensitivity, 85.14% specificity, and 92.73% AUC. Disease: 86.63% accuracy, 95.50% sensitivity,
77.76% specificity, and 91.59% AUC. From the results, we conclude that using heart disease information,
comorbidities, dietary supplement use, and antibiotics enables us to accurately predict the mental
health outcome.
Keywords: heart disease; risk factors; adjusted odds ratio; mental illness prediction; accuracy;
classification; prediction; machine learning; electronic health record
1. Introduction
Heart Disease is one of the most prevalent conditions in developed countries. It is the leading cause
of death in men and women in the United States. Every 37 s, a person dies of Cardiovascular Disease
(CVD) [1]. Around 647,000 Americans die of heart disease every year, which is 1 in every 4 deaths.
Coronary Artery Disease (CAD) is the most common type of heart disease that killed 365,914 people in
2017. About 18.2 million people in the age group of 20 years and older have CVD [2,3]. Patients with
both depression and CVD are three times at risk of mortality than the general population [4,5]. The more
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severe the depression is, the higher the risk of mortality and further complications from CVD events.
The prevalence of depression and anxiety, along with CVD, is bidirectional [6]. This means that the risk
of developing CVD in patients with mental illnesses is high, as is the risk of developing depression and
anxiety in patients with CVD, which may worsen prognosis [7]. Excess mood disorders and anxiety
have been found among people with heart disease irrespective of the countries despite their mental
illness prevalence rate [8].
Several types of research have been conducted to study the risk of heart disease in patients with
mental illnesses. In a study [9] that included 28,734 patients with and without the diagnosed psychotic
disorder, it was revealed that those with diagnosed disorders have a significantly higher risk for
CVD compared to patients without any diagnosed mental illness. Additionally, in a study aimed to
identify CVD risk among veterans, anxiety was associated with CVD mortality in men, and depression
was associated with CVD complications among women [10]. Patients with depressive disorders and
schizophrenia have an increased risk of developing CHD. Anxiety, along with post-traumatic stress
disorder (PTSD), is associated independently with the risk of developing CHD [11,12]. In a case-control
study with 3,211,768 patients and 113,383,368 controls, those with schizophrenia had a higher risk for
CHD, CVD, and congestive heart failure [13].
Among middle-aged women, depression is strongly associated with obesity, lower physical
activity, and a high-calorie diet [14]. Obesity increases the risk of developing depression as obese
individuals have a higher prevalence of depressive disorders. Additionally, depression was also
found to be predictive of obesity [15]. A cross-sectional study on 151,389 patients (age ≥ 18 years)
with one or more types of anxiety identified the association of anxiety and hypertension [16].
While in [17], a cross-sectional cohort study on 2028 depressed or anxious patients, the analysis
concluded that depression is associated with low systolic blood pressure and less hypertension.
However, both hypertension and systolic, as well as diastolic blood pressure, increased with the use
of antidepressants.
Recurrent antibiotic use is associated with a higher risk of depression and anxiety. The study
concluded that clarithromycin could induce psychosis manifestations among adult and pediatric
patients [18,19]. In addition to that, clarithromycin could induce anxiety, hallucinations, and emotional
liability [18,20], while [21] reported dizziness, derealization, and a sense of running very fast with
no perception of rotation association with emotional liability, panic-anxiety, and unmotivated crying.
In an FDA-sponsored study, clarithromycin showed a 10% increased risk of death from any cause and
a 19% increase of risk in developing CVD [22]. Erythromycin associated psychosis was reported in [23].
When a 28-year-old male with schizophrenia conditions was given erythromycin for pityriasis rosea,
he suffered from akathisia soon after he took the drug. The literature concluded that akathisia may be
induced or precipitated by erythromycin by interfering with other drugs [24].
Although several studies have been conducted to identify the risk factors and the bidirectional
association of mental illnesses and heart disease, the prediction of mental illness among patients
with heart disease in terms of comorbidities, dietary supplement use, and drug usage is sparse.
Therefore, this research serves as an exploratory study to identify the risk factors of mental illnesses
using comorbidities, dietary supplement use, and antibiotic usage in heart disease patients. In addition
to that, the purpose of this research is to accurately predict mental illness (depression, anxiety,
and schizophrenia) in heart disease patients and make use of the data-driven model for a real-time
prediction system in the health care setting. The datasets in the medical application are not well
balanced most of the time, which incurs a highly disproportionate outcome distribution. Our prediction
modeling framework deals with the class imbalance problem. Depression, anxiety, and schizophrenia
are considered as separate targets, while an aggregate of these three mental illnesses as an outcome for
the prediction was also employed in our research.
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2. Materials and Methods
2.1. Variable Selection
Logistic Regression (LR) is a mathematical model that is used to select the statistically significant
variables with p-value < 0.05 . The significant variables are then trained using the methods described
below. In addition to that, adjusted R2 (A−R2) is used for model selection. A good model with useful
variables will have a high adjusted R2. Adding a useless variable reduces the adjusted R2. It is given





, where n is the number of data samples, p is the number of variables in the
model, R2 = 1− DD0 , for a binomial outcome variable. D represents the deviance of the fitted model,









Criteria (BIC) select the best subset of variables by penalizing the fitting model based on the number of




+ p log n.
Four different types of approaches are implemented: no variable selection and no undersampling;
no variable selection but undersampling; variable selection and no undersampling; variable selection
and undersampling. For the approaches that involve variable selection, logistic regression that selects
the statistically significant variables (p-value < 0.05), adjusted R2, and BIC are all implemented before
the sampling procedure. A similar approach was discussed in [25], where three different approaches
were considered in terms of sampling and variable selection. In the literature mentioned, Approach 1
selected the features after sampling, but unsampled data was retained. Approach 2 selected the
features after sampling, but the sampled data was retained. Approach 3 sampled after the feature
selection. The literature concluded that Approach 1 performed better. In our research, only Approach 3
was assimilated.
2.2. Prediction
Machine learning, in its broad-spectrum, learns from the data using any computational algorithm
applied to a data sample [26]. The computational model created is used to automatically improve the
prediction through pattern recognition or function approximation by using training or historical data.
The model created using training data is then tested on the test data set. Some of the model metrics to
assess the trained model are explained in detail in the later section. Using these metrics, the best model
of interest is chosen for prediction. Machine learning applications are widespread in many kinds of
research, which include but are not limited to health care and other clinical studies.
Some of the machine learning algorithms used in this study for predicting mental illnesses are
Random Forest (RF) [27], Decision Tree (DT) [28], Naïve Bayes (NB), Extreme Gradient Boosting
(XGBoost) [29], LightGBM (LGBM) [30], and Artificial Neural Networks (ANN) [31]. Random Forest
is an ensemble of methods that create a multitude of decision trees at training time for each of the
randomly selected bootstrap samples. Using bagging, the Random Forest classifier selects the best
split of decision trees among the samples considered during each training step. Prediction on the new
data is based on the aggregation of all the decision trees at each step of the training using the majority
vote. Decision Tree uses a tree-based classification based on the input features. The non-leaf node
represents input features; the leaf node represents target features. Using the information criterion such
as Gini Index, Mutual Information, etc., the inputs are split so that they provide the most information,
and the target features are classified. The features are recursively split into nodes until the tree
reaches a stopping criterion. Naïve Bayes is a probabilistic model that assumes that all the features
are independent. The name comes from the naïve assumption that the features are independent.
Using conditional probability between the features and the target, the posterior probability is computed
based on Bayes’ theorem. Extreme Gradient Boosting is one of the ensemble learning methods that
use boosting. This is similar to [32] but is faster and scalable compared to Gradient Boosting Machine
(GBM). This algorithm is tree-based learning similar to the Random Forest that uses a distributed
gradient boosting technique. Weak learners are added to improve the performance and make it a strong
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learner. One weak learner might not work well on the data, but the addition of new weak learner will
relatively improve the performance. Boosting determines which weak learner should be added next
for the given data. This aggregation of weak learners during the training becomes a strong learner
and improve model performance. This methodology is implemented in the distributed framework
in XGB to make the computation fast and provide accurate predictions. LightGBM is a tree-based
learning algorithm similar to XGB. LightGBM has a faster training speed and offers higher accuracy
most of the time. This has low memory usage and parallel computing support. This works well on big
datasets with larger dimensions and in the cases where the dataset occupies memory. ANN is a neural
network model with one or more hidden layers between input and output layers. It approximates
classification mathematically for linear and non-linear features. Each layer is fully connected to the
previous nodes. Each of the connected nodes is associated with weights. At the training, based on the
objective function used, the probability of the weights reaches a certain threshold, and the neurons are
fired, which means that the respective fired neurons add more weight in the prediction process.
The dataset is split into a 70% training set and a 30% test set. The dataset is highly imbalanced;
therefore, the dataset is undersampled using Synthetic Minority Over-sampling Technique (SMOTE) [33]
to match the number of minority classes. With undersampling, the information, as opposed to the
original sample size, is still retained. The sampling procedure depends on the approach, which will be
covered in the upcoming sections. Classification algorithms are modeled on the training set for four
different targets using 5-fold cross-validation. The test set is used for prediction after the model fitting.
2.3. Performance Measure
The aforementioned algorithms are assessed based on accuracy, recall (sensitivity), F1-score,
specificity, and Area Under the ROC (Receiver Operating Characteristic) Curve (AUC). True Positive
(TP) is the number of correctly classified non-mental illness cases. True Negative (TN) is the
number of correctly classified mental illness cases. False Positive (FP) is the number of incorrectly
classified non-mental illness cases as mental illness cases. False Negative (FN) is the number of
incorrectly classified mental illness cases as non-mental illness cases. Accuracy measures the proportion
of correctly classified non-mental and mental illness cases against all the samples. Accuracy is
given by Accuracy = TP+TNTP+FP+FN+TN . Recall measures the proportion of actual non-mental illness
cases classified correctly against all the non-mental illness case samples. The recall is given by
Recall(Sensitivity) = TPTP+FN . F1-Score measures the average of precision and recall. F1-score is given





, where Precision = TPTP+FP , measures the proportion of correctly classified
non-mental illness cases against all the classification of non-mental illness cases. If F1-score is high,
then both precision and recall is better. Specificity is the measure of correctly classified mental
illness cases against all the sample’s mental illness cases. Specificity is given by Speci f icity = TNTN+FP .
ROC measures the True Positive Rate (TPR) against the False Positive Rate (FPR) at different thresholds.
The AUC value determines the area under this ROC curve. The higher the value of AUC better the
model in terms of differentiating between mental and non-mental illness cases.
Many researchers inculcated machine learning and artificial neural networks in the health care
domain. Machine learning finds its application in a wide range of healthcare-related problem-solving
capabilities. Some of the key research has been done in the area of heart disease prediction and mental
illness’ association with heart disease. Authors in [34] generated risk prediction models for patients
with severe mental illness, such as schizophrenia, along with gender, age, diabetes, Body Mass Index
(BMI), as well as the use of antidepressants and other antipsychotic drugs. This risk prediction model
proved to be better than the Framingham model [35]. For a large population in eastern China with
high-risk CVD, a prediction model for a three-year risk assessment was implemented using random
forest on 29,930 subjects [36]. The diagnosis of coronary artery disease was conducted using the
Classification and Regression Tree (CART) in [37]. In [38], using the Cleveland heart disease dataset
from the UCI machine learning repository, coronary artery disease was classified by Naïve Bayes.
For the National Health and Nutrition Examination Survey (NHANES) dataset and the Framingham
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Heart Study CHS dataset, the XGB algorithm was implemented to predict cardiovascular disease [39].
A deep belief network, one of the most common deep learning classifiers, was used to diagnose the
Coronary Artery Disease (CAD) using the 24-h ECG signal segments [40].
Python v3.7 and R version 3.6.3 using Jupyter IDE are used for the analysis. Pandas package in
Python is used for data wrangling. Preprocessing of data was carried out using sklearn package in Python.
The adjusted odds ratio is implemented using the package statsmodels in Python. The undersampling
procedure is implemented using imblearn package in Python. Variable selection is implemented using
leaps package in R programming. The variables selected in R programming are used to select the
attributes in the dataframe in Python for creating a prediction model. The prediction models Random
Forest, Decision Tree, and Naïve Bayes are created using sklearn package in Python. XGBoost is
implemented using xgboost package in Python. LightGBM is implemented using lightgbm package in
Python. The artificial neural network structure is created using keras package with TensorFlow backend
in Python. The performance measures are implemented in Python.
3. Results
3.1. Dataset
The study protocol was reviewed and approved by the Internal Review Boards of United
Health Services (UHS) and Binghamton University. Typically, patients at their first visit undergo a
comprehensive medical screening for a history of medical and mental conditions, which is updated at
follow-up visits. The dataset was deidentified prior to receipt, including only a few interest variables
to the research team. The age-groups were aggregated to minimize the identification of the patients.
A de-identified database of 68,647 heart disease patient records was provided by the Cardiology Group
at UHS. Upon receipt, the data was stored on the computer of one of the principal investigators with a
strong password. The database was only shared with individuals involved directly in the analysis of
data. The database included gender, age bracket in 10-year increment, BMI, type of heart disease, list of
comorbidities and supplement use, laboratory results, antibiotic use, and mental health. Heart diseases
include Coronary Heart Disease (CHD), Cardiovascular Disease (CVD), Congenital Disease of Heart
(CDH). The data representation for heart diseases is 0 for patients with no heart disease and 1 for
patients with that specific heart disease. To better understand the associations, the attributes of CHD,
CVD, and CDH are all considered as individual attributes. The categorical attributes are represented
by 0 for no and 1 for yes. The mental illness included depression, anxiety, and schizophrenia,
which were represented by 0 or 1; in which 1 represents a patient with that specific mental illness.
The attributes are encoded and preprocessed using sklearn package in Python 3.7. Table 1 shows
the number of observations and percentage distribution of the mental illness and non-mental illness
patients segregated by the category of each attribute. A computed column, Disease, is added to the
dataset as a target. Disease is 1 if either depression = 1 or anxiety = 1 or schizophrenia = 1 or if all the
three mental illnesses represent 1. It is 0 if all three mental illnesses represent 0. The total number
of rows with any one of the mental illnesses (Disease) accounts for 32.61%. The non-mental illness
patients represent 67.39% of the dataset. The columns LAB and LabValue contains 97% missing data,
while Gender had 1 row of unidentified gender listed in the data; therefore, these two columns and one
of the unidentified gender rows were removed from the analysis. Of the total 68,646 rows, the number
of the missing values in the whole dataset account for 437 rows, of which 434 rows of missing values
correspond to the attribute BMI and three missing values in the attribute Gender. Consequently, a total
of 68,209 rows and 29 columns were used for the research. The target columns here are depression,
anxiety, schizophrenia, and disease. Table 2 shows the number of observations and the percentage
distribution of a combination of mental illnesses. A summary of patients with one or more than one
mental illness is listed in the table.
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Variables n % n % n % n % n % n %
Total 68,209 100.0 45,968 67.39 22,241 32.61 10,080 14.72 15,229 22.24 258 0.38
Gender b
Male 37,959 44.35 23,552 51.26 6698 30.12 2912 28.89 4445 29.19 150 58.14
Female 30,250 55.65 22,416 48.76 15,543 69.88 7168 71.11 10,784 70.81 108 41.86
Age (Years)
0–10 487 0.71 237 0.52 250 1.12 25 0.25 229 1.50 0 0.0
11–20 2637 3.87 634 1.38 2003 9.01 858 8.51 1455 9.55 5 1.94
21–30 4641 6.80 1264 2.75 3377 15.18 1312 13.02 2571 16.88 19 7.36
31–40 5647 8.28 2235 4.86 3412 15.34 1402 13.91 2517 16.53 46 17.83
41–50 7727 11.33 4368 9.50 3359 15.10 1521 15.09 2356 15.47 34 13.18
51–60 13,491 19.78 9480 20.62 4011 18.03 1944 19.29 2632 17.28 72 27.91
61–70 14,811 21.71 11,789 25.65 3022 13.59 1556 15.44 1787 11.73 61 23.64
>70 18,768 27.51 15,961 34.72 2807 12.62 1462 14.50 1682 11.04 21 8.14
IDD
No 67,481 98.93 45,365 98.69 22,115 99.43 10,013 99.34 15,157 99.53 253 98.06
Yes 729 1.07 603 1.31 126 0.57 67 0.66 72 0.47 5 1.94
HT
No 48,777 28.49 5718 12.44 13,714 61.66 5847 58.01 9739 63.95 152 58.91
Yes 19,433 71.51 40,250 87.56 8527 38.34 4233 41.99 5490 36.05 106 41.09
OA
No 65,501 96.02 43,933 95.57 21,567 96.97 9714 96.37 14,785 97.08 248 96.12
Yes 2709 3.97 2035 4.43 674 3.03 366 3.63 444 2.92 10 3.88
CM
No 68,016 99.72 45,808 99.65 22,207 99.85 10,063 99.83 15,209 99.87 258 100.0
Yes 194 0.28 160 0.35 34 0.15 17 0.17 20 0.13 0 0.0
Obesity
No 59,601 87.38 39,346 85.59 20,255 91.07 9019 89.47 13,974 91.76 226 87.60
Yes 8609 12.62 6622 14.41 1986 8.93 1061 10.53 1255 8.24 32 12.40
CDH
No 68,153 99.92 45,918 99.89 22,234 99.97 10,076 99.96 15,225 99.97 258 100.0
Yes 57 0.08 50 0.11 7 0.03 4 0.04 4 0.03 0 0.0










No 66,069 96.86 44,189 96.13 21,879 98.37 9876 97.98 15,005 98.53 256 99.22
Yes 2141 3.14 1779 3.87 362 1.63 204 2.02 224 1.47 2 0.78
CVD
No 68,115 99.86 45,899 99.85 22,215 99.88 10,063 99.83 15,216 99.91 257 99.61
Yes 95 0.14 69 0.15 26 0.12 17 0.17 13 0.09 1 0.39
AS
No 68,145 99.90 45,915 99.88 22,229 99.95 10,071 99.91 15,222 99.95 258 100.0
Yes 65 0.10 53 0.12 12 0.05 9 0.09 7 0.05 0 0.0
CAD
No 59,504 87.24 38,433 83.61 21,070 94.73 9455 93.80 14,523 95.36 245 94.96
Yes 8706 12.76 7535 16.39 1171 5.27 625 6.20 706 4.64 13 5.04
ND
No 68,121 99.87 45,901 99.85 22,219 99.90 10,075 99.95 15,213 99.989 256 99.22
Yes 89 0.13 67 0.15 22 0.10 5 0.05 16 0.10 2 0.78
E-CRP
No 67,969 99.65 45,800 99.63 22,168 99.67 10,059 99.79 15,167 99.59 256 99.22
Yes 241 0.35 168 0.37 73 0.33 21 0.21 62 0.41 2 0.78
E-ESR
No 67,900 99.55 45,757 99.54 22,142 99.55 10,039 99.59 15,154 99.51 258 100.0
Yes 310 0.45 211 0.46 99 0.45 41 0.41 75 0.49 0 0.0
LTUA
No 67,911 99.56 45,715 99.45 22,195 99.79 10,058 99.78 15,195 99.78 258 100.0
Yes 299 0.44 253 0.55 46 0.21 22 0.22 34 0.22 0 0.0
BMI c
(mean ± std) (50.25 ± 1108.60)
Underweight (<18.5) 1323 1.93 616 1.34 707 3.18 225 2.23 563 3.70 3 1.16
Normal
(18.5–24.99) 12,535 18.38 7062 15.36 5473 24.61 2142 21.25 4008 26.32 59 22.87
Overweight
(25–29.99) 18,757 27.50 12,939 28.14 5817 26.15 2532 25.12 4052 26.61 84 32.56
Obese
(30–39.99) 26,075 38.23 18,720 40.72 7532 33.06 3571 35.43 4803 31.54 88 34.11
Severe Obese (≥40) 9523 13.96 6631 14.43 2892 13.00 1610 15.97 1803 11.84 24 9.30










CRP 595 41.01 382 42.97 213 37.90 87 38.16 170 38.81 0 0.00
ESR 856 58.99 507 57.03 349 62.10 141 61.84 268 61.19 1 100.0
LabValue e (mean ± std) (17.79 ± 28.97)
E_Mycin
No 68,192 99.97 45,958 99.98 22,233 99.96 10,076 99.96 15,223 99.96 258 100.0
Yes 18 0.03 10 0.02 8 0.04 4 0.04 6 0.04 0 0.00
C_Mycin
No 67,636 99.16 45,619 99.24 22,016 98.99 9988 99.09 15,066 98.93 257 99.61
Yes 574 0.84 349 0.78 225 1.01 92 0.91 163 1.07 1 0.39
Z_Pak
No 48,024 70.41 33,374 72.60 14,649 65.86 6437 63.86 9969 65.46 201 77.91
Yes 20,186 29.59 12,594 27.40 7592 34.14 3643 36.14 5260 34.54 57 22.09
Folate
No 68,131 99.88 45,921 99.90 22,209 99.86 10,062 99.82 15,209 99.87 257 99.61
Yes 79 0.12 47 0.10 32 0.14 18 0.18 20 0.13 1 0.39
VitB6
No 68,050 99.77 45,862 99.77 22,187 99.76 10,054 99.74 15,194 99.77 258 100.0
Yes 160 0.23 106 0.23 54 0.24 26 0.26 35 0.23 0 0.00
CoQ
No 67,589 99.09 45,490 98.96 22,098 99.36 10,017 99.37 15,137 99.40 258 100.0
Yes 621 0.91 478 1.04 143 0.64 63 0.63 92 0.60 0 0.0
O3FO
No 68,026 99.73 45,823 99.68 22,202 99.82 10,058 99.78 15,202 99.82 257 99.61
Yes 184 0.27 145 0.32 39 0.18 22 0.22 27 0.18 1 0.39
Abbreviations: AS, Atherosclerosis; BMI, Body Mass Index; CAD, Coronary Artery Disease; CDH, CongenitalDiseaseOfHeart; CM, CancerMalignant; CVD, Cardiovascular Disease;
C_Mycin, Clarithromycin; CoQ, Coenzyme Q10; E-CRP, Elevated C-reactive Protein; E-ESR, Elevated Erythrocyte Sedimentation Rate; E_Mycin, Erythromycin; HF, HeartFailure;
HT, Hypertension; IDD, InsulinDependentDiabetes; LTUA, LongTermUseOfAntibiotics; LV, LabValue; ND, NutritionDeficiency; O3FO, Omega3FishOil; OA, Osteoarthritis;
VitB6, Vitamin B-6; Z_Pak, Azithromycin; a Some variable names are abbreviated to display the complete table; b One unidentified gender and missing data values for three
patients (0.006%); c Body Mass Index (BMI) missing data values for 434 patients (0.6%); d LAB missing data values for 67, 195 patients (97.8%); e LabValue with miscellaneous values for
six patients, < 0.3 for 10 patients, < 0.1 for three patients, and missing data values for 67, 195 patients (97.8%).
J. Pers. Med. 2020, 10, 214 9 of 17




Non-Disease Depression Anxiety Schizophrenia (D, A) a (D, S) b (A, S) c (A, D, S) d
n % n % n % n % n % n % n % n %
45,968 67.39 10,080 14.78 15,229 22.33 258 0.38 3261 32.35 36 0.36 39 0.26 10 0.31
Abbreviations: A, Anxiety; D, Depression; S, Schizophrenia; a The tuples indicate patients with both depression
(D) and anxiety (A). b The tuples indicate patients with both depression (D) and schizophrenia (S). c The tuples
indicate patients with both anxiety (A) and schizophrenia (S). d The tuples indicate patients who have anxiety (A),
depression (D) as well as schizophrenia (S).
3.2. Association of Dietary Supplements, Comorbidities and Drug Usage in Mental Illness Patients
Some of the previous literatures use odds ratio and adjusted odds ratio to identify the risk factors.
Psychosis had the largest effect among males and females on CVD among veterans with mental
illnesses. The literature used an adjusted odds ratio to determine the effect [10]. Patients with two or
more anxiety symptoms had CHD risk and sudden death, which was identified using an adjusted
odds ratio [12]. The meta-analysis conducted in [15] showed a reciprocal link between obesity and
depression using the odds ratio. A cross-sectional study on 151,389 patients (age ≥ 18 years) with
one or more types of anxiety used final pooled odds ratio and the pooled adjusted hazard ratio to
identify the association of hypertension with anxiety [18]. Based on the odds ratio and the associated
confidence interval (CI) as well as the p-value, suicidal behavior risk factors are identified in [41].
Multivariate logistic regression was used to analyze the association between suicidal behavior and
the factors mentioned above. In [18], a case-controlled study was implemented on a medical records
database in the UK to study the association of antibiotic exposure on depression, anxiety, and psychosis.
Tables 3–6 shows the odds ratio for depression, anxiety, schizophrenia, and disease. The tables show
the number of patients with the mental illness, each attribute’s upper and lower confidence interval
under a 95% confidence interval, adjusted odds ratio with its associated p-value. Each of the attributes
listed is statistically significant under a 95% confidence interval. The predictors with p-value > 0.05
are excluded from the analysis. The odds ratio listed is an adjusted odds ratio which accounts for
confounding variables. The disease represents all three mental illnesses as described in the previous
section. Since age is not a continuous attribute, the 10-year increment in the age group is categorized
with the age group 0–10 representing a reference level. BMI is categorized for the sake of understanding
which BMI level is a risk factor for mental illnesses.
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Table 3. Association of dietary supplements, antibiotics, and comorbidities for depression.
N a LCL b UCL c aOR d p-Value
age
0–10 Ref e
11–20 858 4.4327 10.2297 6.7335 0.0000
21–30 1312 3.8046 8.7597 5.7730 0.0000
31–40 1402 4.0315 9.2835 6.1178 0.0000
41–50 1521 4.1224 9.4920 6.2551 0.0000
51–60 1944 3.6822 8.4682 5.5840 0.0000
61–70 1556 2.9935 6.8981 4.5440 0.0000
Over–70 1462 2.3545 5.4319 3.5762 0.0000
Gender
Male Ref
Female 7168 1.6113 1.7788 1.6930 0.0000
Z_Pak 3643 1.3227 1.4563 1.3879 0.0000
BMI
<18.5 Ref
>=40 1610 1.0832 1.5228 1.2843 0.0040
Osteoarthritis 366 0.6892 0.8760 0.7770 0.0000
CoronaryArteryDisease 625 0.6284 0.7547 0.6887 0.0000
Obesity 1061 0.4774 0.5561 0.5153 0.0000
Hypertension 4233 0.2373 0.2653 0.2509 0.0000
a Number of patients with depression; b Lower Confidence Limit; c Upper Confidence Limit; d Adjusted Odds Ratio;
e Reference level.
Table 4. Association of dietary supplements, antibiotics, and comorbidities for anxiety.
N a LCL b UCL c aOR d p-Value
Gender
Male Ref e
Female 10,784 1.7604 1.9275 1.8421 0.0000
Clarithromycin 163 1.4329 2.1862 1.7699 0.0000
Intercept 1.4021 2.1573 1.7392 0.0000
Z_Pak 5260 1.4481 1.5880 1.5163 0.0000
CoQ 92 1.1736 1.8996 1.4932 0.0011
age
0–10 Ref
21–30 2571 1.1618 1.7834 1.4394 0.0009
31–40 2517 1.0576 1.6216 1.3096 0.0134
51–60 2632 0.5436 0.8317 0.6724 0.0003
61–70 1787 0.3454 0.5304 0.4280 0.0000
>70 1682 0.2489 0.3827 0.3086 0.0000
HeartFailure 224 0.6440 0.8746 0.7505 0.0002
BMI
<18.5 Ref
18.5–24.99 4008 0.5725 0.7615 0.6603 0.0000
25–29.99 4052 0.4727 0.6286 0.5451 0.0000
30–39.99 4803 0.3818 0.5078 0.4403 0.0000
>=40 1803 0.3542 0.4796 0.4121 0.0000
Osteoarthritis 444 0.5357 0.6772 0.6023 0.0000
CoronaryArteryDisease 706 0.5396 0.6439 0.5894 0.0000
ElevatedCRP 62 0.3983 0.7934 0.5621 0.0011
Obesity 1255 0.3027 0.3519 0.3264 0.0000
Hypertension 5490 0.1857 0.2055 0.1954 0.0000
a Number of patients with anxiety; b Lower Confidence Limit; c Upper Confidence Limit; d Adjusted Odds Ratio;
e Reference level.
Table 5. Association of dietary supplements, antibiotics, and comorbidities for schizophrenia.
N a LCL b UCL c aOR d p-Value
Z_Pak 57 0.5168 0.9400 0.6970 0.018
Gender
Male Ref e
Female 108 0.3436 0.5766 0.4451 0.0000
Hypertension 106 0.1567 0.2823 0.2103 0.0000
a Number of patients with schizophrenia; b Lower Confidence Limit; c Upper Confidence Limit; d Adjusted Odds
Ratio; e Reference level.
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Table 6. Association of dietary supplements, antibiotics, and comorbidities for the disease.
N a LCL b UCL c aOR d p-Value
age
0–10 Ref e
11–20 2003 2.0997 3.3290 2.6438 0.0000
21–30 3377 2.4145 3.7744 3.0189 0.0000
31–40 3412 2.1247 3.3040 2.6496 0.0000
41–50 3359 1.5622 2.4222 1.9453 0.0000
51–60 4011 1.0804 1.6695 1.3430 0.0079
>70 2807 0.5097 0.7887 0.6341 0.0000
Intercept 1.8792 2.9404 2.3507 0.0000
Gender
Male Ref
Female 15,543 2.0153 2.1931 2.1024 0.0000
Clarithromycin 225 1.4559 2.1904 1.7857 0.0000
Z_Pak 7592 1.5693 1.7137 1.6398 0.0000
VitB6 54 1.0515 2.4383 1.6011 0.0283
CoQ 143 1.2244 1.8736 1.5145 0.0001
BMI
<18.5 Ref
18.5–24.99 5473 0.5887 0.7924 0.6830 0.0000
25–29.99 5817 0.4823 0.6479 0.5590 0.0000
30–39.99 7352 0.4246 0.5702 0.4921 0.0000
>=40 2892 0.4342 0.5913 0.5067 0.0000
ElevatedESR 99 0.4614 0.8791 0.6369 0.0061
HeartFailure 362 0.5487 0.7188 0.6280 0.0000
CoronaryArteryDisease 1171 0.4861 0.5663 0.5247 0.0000
Osteoarthritis 674 0.4119 0.5139 0.4601 0.0000
ElevatedCRP 73 0.1946 0.3936 0.2768 0.0000
Obesity 1986 0.2164 0.2501 0.2327 0.0000
Hypertension 8527 0.0987 0.1094 0.1039 0.0000
InsulinDependentDiabetes 126 0.0778 0.1216 0.0973 0.0000
a Number of patients with disease; b Lower Confidence Limit; c Upper Confidence Limit; d Adjusted Odds Ratio;
e Reference level.
3.3. Modeling the Mental Illness Prediction Framework
While there was no hyperparameter tuning involved, the model was trained using the default
parameter settings for all the algorithms except ANN. For the decision tree, entropy was used as the
information criterion. For ANN, the network is designed with 24 neuron-input layers, one hidden layer
of 16 neurons, and an output layer. Early stopping criteria were imposed on AUC, which used an Adam
optimizer and a Binary Cross Entropy-loss function. A drop-out layer with a probability of 0.5 was used
to avoid overfitting. The illnesses are trained as separate targets using random forest, decision tree,
Naïve Bayes, XGB, LightGBM, and ANN using 5-fold cross-validation. During variable selection for
some of the approaches, the variables are selected using either adjusted R2, logistic regression, or BIC
before undersampling. Adjusted R2 and BIC is implemented using R programming, while logistic
regression is implemented in python to select the best variable set. After undersampling using SMOTE,
the sampled data is split into 5-folds, while in each of the folds, the test set is predicted. At the end of
the fold, the reported metrics are the average of the 5-folds. The best performing model is selected
based on AUC. The threshold for identifying positive and negative class is 0.5 because the data is
balanced using undersampling. The reported values are the average of the 5-folds. The table shows the
best performing model using different approaches and the considered algorithms. The comparison of
the baseline models and the models trained using the approaches are all reported in the Supplementary
material. Table 7 shows a comparison of four approaches for each mental illness. Under the variable
selection column in the table, the respective variable selection methodology used is listed, when it is
applied. When no such approach is used, it is listed as no. Yes/no undersampling column represent the
application of undersampling procedure for the respective model. A model with no variable selection
and no undersampling is the baseline model for the targets. The top row in each of the mental illness
categories is the best prediction model.
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Table 7. Prediction performance of four different approaches for mental illnesses.
Illness Variable Selection Under Sampling Model Accuracy F1-Score Sensitivity Specificity AUC
Depression
A-R2 Yes LGBM 0.7801 0.7913 0.8338 0.7265 0.8626
No Yes LGBM 0.7648 0.7745 0.8083 0.7214 0.8518
No No LGBM 0.8530 0.9199 0.9903 0.0615 0.7648
LR No LGBM 0.8524 0.9201 0.9974 0.0160 0.7567
Anxiety
A-R2 Yes LGBM 0.8293 0.8286 0.8251 0.8335 0.8845
No Yes LGBM 0.8242 0.8231 0.8178 0.8306 0.8775
No No LGBM 0.8558 0.9100 0.9380 0.5701 0.8318
LR No LGBM 0.8550 0.9091 0.9331 0.5833 0.8289
Schizophrenia
LR Yes RF 0.8759 0.8770 0.8976 0.8514 0.9292
No Yes RF 0.8779 0.8799 0.8983 0.8544 0.9268
No No XGB 0.9962 0.9981 1.0000 0.0000 0.7423
LR No XGB 0.9962 0.9981 1.0000 0.0000 0.7361
Disease
No Yes LGBM 0.8663 0.8772 0.9550 0.7776 0.9159
A-R2 Yes XGB 0.8670 0.8788 0.9646 0.7695 0.9130
No No LGBM 0.8565 0.9035 0.9971 0.5659 0.8522
LR No LGBM 0.8555 0.9028 0.9957 0.5656 0.8515
4. Discussion
4.1. Risk Factors of Mental Illness
The interpretation of the odds ratio is provided in the supplementary material. In Table 3,
age brackets 11–20, 21–30, 31–40, 41–50, 51–60, 61–70, and >70 are associated with depression.
In addition to that, the female population has higher odds of depression compared to the male
population. People who take Z_Pak are likely to have depression compared to the population that does
not take it. With < 18.5 kg/m2 as the reference level for BMI, people with BMI ≥ 40 kg/m2 are likely
to be diagnosed with depression. Although other attributes listed like osteoarthritis, coronary artery
disease, obesity, and hypertension have a lower association with depression, [11,12] mentioned coronary
heart disease as one of the risk factors. This partially matched with our analysis. [14,15] concluded
that obesity is associated with depression. Although there is no strong association encountered,
obesity is associated with lower odds of depression. Similarly, hypertension has lower odds of depression,
as mentioned in [17].
In Table 4, the female population has higher odds of developing anxiety compared to the male
population. People who take clarithromycin, Z_Pak, and CoQ have higher odds of developing anxiety.
Only the age groups 21–30 and 31–40 are susceptible to developing anxiety. The other predictors listed
show lower odds of developing anxiety. Coronary artery disease is associated with lower odds of anxiety,
which partially match with [11,12]. In addition to that, hypertension is associated with lower odds of
anxiety, partially matching the conclusions from [16]. Clarithromycin is associated with higher odds of
anxiety, which agrees with [18,20,21].
In Table 5, schizophrenia has a smaller sample size, so the variables selected show association
with lower odds of schizophrenia.
Table 6 represents all three mental illnesses combined. Age groups except for >70 show association
of higher odds of developing mental illness. The Female population is susceptible to mental illness
compared to the male population. Drug intake such as clarithromycin, Z_Pak, VitB6, and CoQ is
associated with higher odds of developing any of the mental illnesses.
4.2. Depression
Compared to the best model (72.65%) the baseline model’s specificity for depression was inaccurate
(0.61%). The lower specificity in the baseline model is mainly due to the imbalanced distribution of
the classes. The prediction of depression is best with the variable selection that uses adjusted R2
and undersampling. LightGBM that uses this approach outperformed on all the metrics compared
to the other models. AUC increased to 86.26% in the case of variable selection in comparison to
no variable selection, which is 85.18%. The performance of other approaches is provided in the
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supplementary material. The increase in AUC is obtained after removing Gender, CerebrovascularDisease,
and elevatedESR. Having these variables in the model had little to no effect on the prediction. The total
number of features in the final model had 21 variables. Since CVD was not one of the predictors of
depression, the bidirectional association [6,7] was not concluded in our study. Although CAD is one of
the predictors for depression, this inference match with [10].
4.3. Anxiety
Specificity for anxiety’s best prediction model using LightGBM (83.35%) is better than the baseline
model’s specificity using LightGBM (57.01%). The specificity of anxiety in the baseline model is high in
comparison to other mental illnesses because it has a large sample size in the dataset among all the other
mental illnesses. There are only two best models that have significantly less difference in performance
for the prediction of anxiety. LightGBM and XGB gave AUC of 88.45% and 87.93% respectively.
These two were obtained using a variable selection that uses adjusted R2 and undersampling. The same
set of variables emerged similar to the case of depression. LightGBM was selected as the best performing
model because it has higher specificity in comparison to XGB. However, the model AUC value was
uplifted from 87.75% (no variable selection with undersampling) to 88.45% with the use of the variable
selection. Similar to depression, CVD was not selected as a predictor for anxiety from the variable
selection. The inference from our research contradicts the bidirectional association in [6,7]. Since CHD
and CDH are all selected as a predictor of anxiety, the results match with [11,12].
4.4. Schizophrenia
The specificity of the best performing model for schizophrenia is 84.14%, which uses random forest,
while the baseline model that uses random forest is 0.74%. Again, it is due to the class imbalance because
schizophrenia has a small sample size in the dataset than the other mental illnesses. Schizophrenia’s
best prediction model was achieved by selecting the statistically significant variables using logistic
regression and undersampling after the selection procedure. A total of seven variables emerged from
this method. The selected variables are Gender, Age, Hypertension, Obesity, CoronaryArteryDisease, BMI,
and Z_Pak. The variables selected are similar to odd’s ratio interpretation for schizophrenia discussed
in Section 4.1. Variables such as gender, age, and BMI are used to create the risk prediction model for
schizophrenia in [34]. It agrees with the risk prediction model created in our research. Since CAD is
selected as one of the predictors of schizophrenia, the results completely agree with [10] and partially
match with [13]. The best model’s AUC using random forest is 92.73%, and the case without variable
selection is 92.56%.
4.5. Disease
For disease, no variable selection with undersampling is the best performing model. Compared to
the baseline model’s specificity (56.59%) using lightGBM, the best model’s specificity using LightGBM
increased (77.76%). Although there is no significant difference between the AUC values of LightGBM
(91.59%) and XGB (91.41%), the specificity for LightGBM (77.76%) is higher than XGB (76.22%).
Therefore, LightGBM, with no variable selection and undersampling is selected as the best performing
disease prediction model.
In all cases, the high model performance was achieved through undersampling, because the
dataset is highly imbalanced. One of the main advantages of LightGBM is the faster training time
on massive datasets. It outperforms other gradient boosting techniques such as XGB as well as the
ANN model due to its distributed high-performance gradient boosting technique. This gradient
boosting-based method captures all the interactions between the predictors better than linear models.
Because the data is well structured, LightGBM performed well for depression, anxiety, and disease.
In schizophrenia, since the sample size is smaller, random forest worked better due to the random
resampling for training the model.
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The best prediction model for depression is LightGBM, which uses variable selection that uses
adjusted R2 and undersampling; it gave 78.01% accuracy, 79.13% sensitivity, 72.65% specificity,
and 86.26% AUC, respectively. A total of 21 variables emerged for depression from the variable
selection. The best model for anxiety is LightGBM, which uses variable selection that uses adjusted R2
and undersampling; it gave 82.93% accuracy, 82.86% sensitivity, 83.35% specificity, and 88.45% AUC,
respectively. Similar to depression, 21 variables emerged. The best model for schizophrenia is the
Random Forest, which uses variable selection that uses logistic regression and undersampling; it gave
87.59% accuracy, 87.70% sensitivity, 85.14% specificity, and 92.73% AUC, respectively. Using logistic
regression, schizophrenia has seven variables. The best model for the disease that aggregates all
the mental illnesses is LightGBM without using variable selection and uses undersampling; it gave
86.63% accuracy, 95.50% sensitivity, 77.76% specificity, and 91.59% AUC, respectively. Prediction of
schizophrenia using our best model was able to achieve high accuracy, followed by a prediction of
the disease, anxiety, and depression. The prediction of the disease using our best model accurately
captured one of the mental illnesses from their heart disease information, which includes antibiotics
and dietary supplement intake.
The healthcare institutions employ an automated prediction system in their diagnostic procedures
while using a wide range of data. It is possible due to the increasing innovation in computational
efficiency and accurate prediction system. A less time-consuming and accurate prediction of illnesses
reduces the cost and time incurred in diagnosing each patient. In this research, a data-driven model to
predict mental illness, which uses the information of comorbidities, dietary supplements, and antibiotics,
is implemented. This research will find its application mainly to diagnose the illness using comorbidities,
dietary supplements, and antibiotics, which is sparse in the medical application to date. The prediction
helps identify the likelihood of mental illness based on the intake of drugs, dietary supplements,
and antibiotics, along with diagnosed heart disease. This research can be useful when employed in
healthcare settings because it helps propose prospective treatment and test procedures that can be
time-consuming when done traditionally.
4.6. Strengths and Limitations of the Study
The study has several strengths and limitations. The large number of records studied, and the
use of several analytical methods are some of its strengths. One of the limitations of this research is
that the patient information comes from only one of the healthcare institutions and does not represent
all the patient population. Diagnostic information and patient’s visit to other healthcare institutions
outside of this hospital are not known. Also, the patients’ intake of other antibiotics and other dietary
supplements for any other purposes other than the aforementioned is not captured in this research.
5. Conclusions
In summary, patients’ demographics in age groups > 10, female population, patients with
BMI ≥ 40 kg/m2, and drug intake like Z_Pak were associated with depression. The female population,
drug intake like clarithromycin, Z_Pak, CoQ, and patients’ demographics in age groups 21–30 and
31–40 were associated with anxiety. Z_Pak is associated with lower odds of schizophrenia. Patients’
demographics in the age group except >70, who is a female, and drug intakes such as clarithromycin,
Z_Pak, VitB6, and CoQ were associated with the disease as such, which are a risk factor.
The best prediction model for depression gave 78.01% accuracy, 79.13% sensitivity, 72.65% specificity,
and 86.26% AUC, respectively. The best model for anxiety gave 82.93% accuracy, 82.86% sensitivity,
83.35% specificity, and 88.45% AUC, respectively. The best model for schizophrenia gave 87.59% accuracy,
87.70% sensitivity, 85.14% specificity, and 92.73% AUC, respectively. The best model for the disease that
aggregates all the mental illnesses gave 86.63% accuracy, 95.50% sensitivity, 77.76% specificity, and 91.59%
AUC. We can predict mental illnesses accurately using the dietary supplements, comorbidities, and drug
usage data of patients with heart disease.
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For future work, the interaction effect of the predictors on depression, anxiety, and schizophrenia
will be considered. Applying the odds ratio to these significant interactions and confounders, the risk
of each of these interactions, and their effect on mental illness will be interpreted. Since only a few
variables are removed instead of selecting a subset of variables for the prediction, traditional subset
selection methodologies did not work for the dataset. Therefore, another direction to pursue is to
improve the prediction performance by applying Bayesian variable selection approaches. Bayesian
net has proved to be useful in many healthcare domains. Applying Bayesian net for mental illness
prediction will also be considered as part of the exploration.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4426/10/4/214/s1,
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Table S2: Average Metrics of 5-fold CV for the Mental Illnesses with no Variable Selection and using Under
Sampling; Table S3: Average Metrics of 5-fold CV for the Mental Illnesses with Variable Selection using Adjusted
R2 and no Under Sampling; Table S4: Variables Selected using Adjusted R2 with no Under Sampling; Table S5:
Average Metrics of 5-fold CV for the Mental Illnesses with Variable Selection using BIC and no Under Sampling;
Table S6: Variables Selected using BIC with no Under Sampling; Table S7: Average Metrics of 5-fold CV for the
Mental Illnesses with Variable Selection using Logistic Regression and no Under Sampling; Table S8: Variables
Selected using Logistic Regression with no Under Sampling; Table S9: Average Metrics of 5-fold CV for the
Mental Illnesses with Variable Selection using Adjusted R2 and Under Sampling; Table S10: Variables Selected
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